FBR & Co reaffirmed their outperform rating on shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) in a report published on Wednesday. The brokerage currently has a $10.00 price objective on the stock.

A number of other brokerages have also recently issued reports on AVXL. Maxim Group reiterated a buy rating and set a $15.00 price objective on shares of Anavex Life Sciences Corp. in a research note on Wednesday, June 22nd. Zacks Investment Research cut Anavex Life Sciences Corp. from a buy rating to a hold rating in a research note on Tuesday, July 12th.

Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) opened at 3.7714 on Wednesday. The stock’s market capitalization is $134.68 million. Anavex Life Sciences Corp. has a 52-week low of $2.43 and a 52-week high of $14.84. The stock has a 50 day moving average of $3.12 and a 200-day moving average of $4.52.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last released its earnings results on Thursday, August 11th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. On average, equities research analysts predict that Anavex Life Sciences Corp. will post ($0.34) EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Anavex Life Sciences Corp. by 47.2% in the first quarter. Geode Capital Management LLC now owns 179,549 shares of the company’s stock worth $879,000 after buying an additional 57,572 shares during the last quarter. Bank of New York Mellon Corp raised its position in Anavex Life Sciences Corp. by 136.8% in the second quarter. Bank of New York Mellon Corp now owns 129,276 shares of the company’s stock worth $790,000 after buying an additional 74,682 shares during the last quarter. California State Teachers Retirement System acquired a new position in Anavex Life Sciences Corp. during the second quarter worth $418,000. Nationwide Fund Advisors acquired a new position in Anavex Life Sciences Corp. during the second quarter worth $130,000. Finally, Vanguard Group Inc. raised its position in Anavex Life Sciences Corp. by 16.4% in the second quarter. Vanguard Group Inc. now owns 1,169,013 shares of the company’s stock worth $7,143,000 after buying an additional 164,686 shares during the last quarter. 10.72% of the stock is currently owned by institutional investors and hedge funds.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

5 Day Chart for NASDAQ:AVXL

Receive News & Stock Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related stocks with our FREE daily email newsletter.